Previous 10 | Next 10 |
DURECT ([[DRRX]] -7.6%) Q3 total revenue $2.7M, compares to $10.8M last year figure.Net loss was $9.3M.At September 30, 2020, cash and investments were $49.8M, compared to cash and investments of $51.3M at June 30.Company continues to communicate with the FDA regarding their review of th...
Image source: The Motley Fool. Durect Corp (NASDAQ: DRRX) Q3 2020 Earnings Call Nov 2, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Durect Corp (DRRX) Q3 2020 Earnings Call Transcript
DURECT Corporation (DRRX) Q3 2020 Earnings Conference Call November 2, 2020 16:30 ET Company Participants Mike Arenberg - Chief Financial Officer Jim Brown - President & Chief Executive Officer WeiQi Lin - Executive Vice President, Research & Development & Principal Scientist Conf...
Durect (DRRX): Q3 GAAP EPS of -$0.05 misses by $0.01.Revenue of $2.68M (-75.1% Y/Y) misses by $1.29M.Cash and investments were $49.8M.Press Release For further details see: Durect EPS misses by $0.01, misses on revenue
DURECT Corporation Announces Third Quarter 2020 Financial Results and Update of Programs Webcast of Earnings Call Today, November 2nd at 4:30 p.m. ET PR Newswire CUPERTINO, Calif., Nov. 2, 2020 CUPERTINO, Calif. , Nov. 2, 2020 /PRNewswire/ -- DURECT Cor...
DURECT Corporation Appoints Dr. Norman Sussman as Chief Medical Officer PR Newswire CUPERTINO, Calif., Nov. 2, 2020 CUPERTINO, Calif. , Nov. 2, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on the development ...
DURECT Corporation to Announce Third Quarter 2020 Financial Results and Provide Business Update on November 02, 2020 PR Newswire CUPERTINO, Calif., Oct. 27, 2020 CUPERTINO, Calif. , Oct. 27, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today ann...
DURECT Corporation to Participate in the ROTH Capital Partners Healthcare Event "Covid-19 Therapeutics in Development" PR Newswire CUPERTINO, Calif., Oct. 26, 2020 CUPERTINO, Calif. , Oct. 26, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today ...
DURECT (DRRX) will present a poster at The AASLD Liver Meeting Digital Experience (TLMdX) 2020, to be held virtually on November 13-16, 2020. Topline results from the 4-week Phase 1b clinical study of orally administered DUR-928 in nonalcoholic steatohepatitis ((NASH)) patients were...
DURECT Corporation to Present Additional Safety and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020 PR Newswire CUERTINO, Calif., Oct. 5, 2020 CUERTINO, Calif., Oct. 5, 2020 /PRNewswir...
News, Short Squeeze, Breakout and More Instantly...
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis PR Newswire DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. , May ...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 171.6% to $0.1657 on volume of 180,907,472 shares AMC Entertainment Holdings Inc. Class A (AMC) rose 84.4% to $9.57 on volume of 174,658,682 shares Plug Power Inc. (PLUG) rose 45.9%...
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update PR Newswire - FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Ea...